- Conditions
- Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
- Interventions
- rF1V-1018, rF1V vaccine
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 28
- States / cities
- Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more
- Conditions
- Hepatitis B
- Interventions
- 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
- Conditions
- Healthy
- Interventions
- HEPLISAV and/or Placebo, Engerix-B
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 2,452 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 29
- States / cities
- Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more
- Conditions
- Hepatitis B
- Interventions
- HEPLISAV
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
- Drug · Device
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
- Conditions
- Metastatic Melanoma, Head Neck Cancer
- Interventions
- SD-101(1), Pembrolizumab, SD-101(2), SD-101(3)
- Drug · Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 26 more
- Conditions
- B-cell Lymphoma
- Interventions
- SD-101, Radiation therapy
- Drug · Radiation
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • Iowa City, Iowa + 2 more
- Conditions
- End Stage Renal Disease on Hemodialysis (Diagnosis)
- Interventions
- HEPLISAV-B®
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
- Conditions
- Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
- Interventions
- rF1V-1018
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Miami, Florida • El Dorado, Kansas • Las Vegas, Nevada + 1 more
- Conditions
- Chronic Kidney Disease
- Interventions
- HEPLISAV, Engerix-B
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Healthy
- Interventions
- SD-101, placebo
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis B
- Interventions
- HEPLISAV
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Boardman, Ohio • Grove City, Pennsylvania • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Chronic Kidney Disease
- Interventions
- HEPLISAV-B, Engerix-B, Placebo
- Biological · Other
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 521 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- HIV Infection, Hepatitis B
- Interventions
- HEPLISAV-B, ENGERIX-B
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 638 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Nivolumab, Radiation Therapy, TLR9 Agonist SD-101
- Biological · Radiation · Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- HIV Infections
- Interventions
- BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
- Conditions
- Pregnant
- Interventions
- HEPLISAV-B
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Colorectal Neoplasms
- Interventions
- 1018 ISS immunostimulatory oligonucleotide
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Rituxan, 1018 ISS
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- HEPLISAV, Engerix-B
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8,374 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more